Regional and temporal differences in gene expression of LH BETAT AG retinoblastoma tumors

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5359-5368

  Houston, Samuel K ^a   Pina, Yolanda ^a   Clarke, Jennifer ^b   Koru Sengul, Tulay ^b   Scott, William K ^b   Nathanson, Lubov ^b   Schefler, Amy C ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; GENE EXPRESSION; HYPOXIA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR LOCALIZATION; ANIMAL; ANOXIA; DISEASE MODEL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; RETINA TUMOR; TUMOR GENE;

OXYGEN; TUMOR PROTEIN;

ANIMALS; ANOXIA; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXYGEN; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 80052012074     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6321     Document Type: Article

References (42)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108:128-132.
2. Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol. 1980;98:1204-1210.
3. Abramson DH. Retinoblastoma incidence in the United States. Arch Ophthalmol. 1990;108:1514.
4. Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol. 1975;80:263-265.
5. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges. The Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683-2691.
6. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118:577-578.
7. Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18:55-63.
8. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378-1383.
9. Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148:192-198.
10. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006;17:228-234.
11. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114:162-169.
12. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820-823.
13. Corson TW, Gallie BL. One hit, two hits, three hits, more?-genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46:617-634.
14. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation. 2002;70:537-546.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
16. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
17. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425-437.
18. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851-864.
19. Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799-2805.
20. Pina Y, Boutrid H, Schefler A, et al. Blood vessel maturation in human and lhbetatag mouse model retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009;50:1020-1024.
21. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
22. Pina Y, Boutrid H, Schefler A, et al. Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009;50:1020-1024.
23. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
24. Team RDC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria;2010.
25. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 1995;9:1233-1243, discussion 1243-1234.
26. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
27. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle. 2004;3:900-904.
28. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444:61-66.
29. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006;25:6202-6210.
30. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53.
31. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897-5901.
32. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol. 2008;2:41-53.
33. Fink T, Kazlauskas A, Poellinger L, Ebbesen P, Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood. 2002;99:2077-2083.
34. Schilling D, Bayer C, Geurts-Moespot A, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer. 2007;7:143.
35. Bajenaru ML, Pina Y, Murray TG, et al. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci. 2010;51:2860-2864.
36. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
37. Tennant DA, Duran RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis. 2009;30:1269-1280.
38. King A, Gottlieb E. Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr Opin Cell Biol. 2009;21:885-893.
39. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267-277.
40. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics. 2007;90:344-353.
41. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278-2287.
42. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis. 2010;16: 1292-1303.